Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)
Auburn University · with Indiana University · NCT06062017
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–30 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 40
- US sites recruiting
- 1
- Study start
- November 6, 2024
- Record last updated
- February 27, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Compared with White Adults, Non-Hispanic Black Adults are at an elevated risk of developing cardiovascular disease (CVD) and end stage chronic-kidney disease (CKD), two of the leading causes of death in the United States. Inadequate hydration status is associated with risk factors for both CVD and CKD. Prior data show that Black individuals are less likely to be adequately hydrated when compared with their White counterparts. Further, socioeconomic factors have been shown to influence hydration practices. Inadequate hydration influences certain hormones that regulate blood volume and impact blood pressure, but increasing potassium intake may provide some positive effects on normalizing these hormones and blood pressure. Black adults, in particular, are more likely to consume less potassium, have inadequate hydration, and tend to have higher blood pressure. As such, there is a critical need for effective strategies to address racial disparities in hydration and resultant health consequences; as well as establish the role of socioeconomic factors contributing to hydration. Therefore, the investigators are seeking to test the investigators' central hypothesis that water with a potassium supplement will improve hydration and cardiovascular health in young White adults (n = 20, 10 females, 10 males), and to a greater extent in young Black Adults (n = 20, 10 females, 10 males. The investigators will assess measures of blood pressure, arterial stiffness, and biomarkers in the urine and blood samples prior to and following a 14-day hydration intervention of 1) bottled water and 2) bottled water with potassium supplementation (2000mg potassium/day).
Being studied: Water and Potassium supplementation
Conditions: Blood Pressure; Hydration; Vascular Disease Risk
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Between the ages of 18-30 years
- Resting blood pressure no higher than 150/90 mmHg
- BMI below 35 kg/m2
- Free of any metabolic disease (e.g., diabetes) kidney disease, pulmonary disorders (e.g., COPD), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular), no autoimmune diseases, and no history of cancer.
Exclusion Criteria
- Have any precluding medical conditions (i.e. hemophilia) or medication (Pradaxa, Eliquis, etc.) that prevent participants from giving blood.
- Are currently pregnant or trying to become pregnant.
- take any of the following medications that are contraindicated with potassium supplementation:
- Renin-angiotensin-aldosterone system (RAAS) blockers: Candesartan , Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan
- Non -steroidal anti-inflammatory medications: Aspirin, Ibuprofen, Naproxen
- Non-selective beta-blockers: Pindolol, Penbutolol, Oxprenolol, Propranolol, Nadolol, Sotalol, Timolol, Tertatolol
- Calcineurin inhibitors: Cyclosporine
- Heparin (or other blood thinning medications)
Recruiting US locations
Kinesiology Building
Auburn, AL 36849
Site contact: Nina L Stute, MS · 334-844-1619 · nls0028@auburn.edu
Study contacts (from the official record)
- Nina L Stute, M.S. · 9373071608 · NLS0028@auburn.edu
- Meral A Culver, M.S. · 3017428813
Similar studies in Alabama
All heart & blood pressure studies in Alabama →- RecruitingHealthy volunteersPhase 1
Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project
University of Alabama at Birmingham
- Location
- Birmingham, AL
- Eligibility basics
- Ages 14–89 · Women only
- Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics
- Location
- Birmingham, AL + 64 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Merck Sharp & Dohme LLC
- Location
- Alexander City, AL + 23 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Prevail Global Study
Medtronic Vascular
- Location
- Birmingham, AL + 53 other US sites
- Eligibility basics
- Ages 18+